| $385M | ||
| $337M | ||
| $100M | ||
| $87M | ||
| $82M | ||
| $62M |
Buys | $107,086 | 3 | 100 |
Sells | $0 | 0 | 0 |
| Lehr Martin A. | Chief Executive Officer | 1 | $70,080 | 0 | $0 | $70,080 |
| Minai-Azary Jennifer Lynn | Chief Financial Officer | 1 | $25,486 | 0 | $0 | $25,486 |
| Levit Alex C. | Chief Legal Officer, Corp. Sec | 1 | $11,520 | 0 | $0 | $11,520 |
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Over the last 12 months, insiders at Context Therapeutics Inc. have bought $107,086 and sold $0 worth of Context Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Context Therapeutics Inc. have bought $88,097 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lehr Martin A. (Chief Executive Officer) — $70,080. Minai-Azary Jennifer Lynn (Chief Financial Officer) — $25,486. Levit Alex C. (Chief Legal Officer, Corp. Sec) — $11,520.
The last purchase of 100,000 shares for transaction amount of $70,080 was made by Lehr Martin A. (Chief Executive Officer) on 2025‑06‑09.
| 2025-06-09 | Lehr Martin A. | Chief Executive Officer | 100,000 0.1111% | $0.70 | $70,080 | +24.27% | ||
| 2025-06-06 | Minai-Azary Jennifer Lynn | Chief Financial Officer | 40,010 0.0428% | $0.64 | $25,486 | +31.49% | ||
| 2025-06-06 | Levit Alex C. | Chief Legal Officer, Corp. Sec | 20,000 0.0193% | $0.58 | $11,520 | +31.49% | ||
| 2023-02-21 | Lehr Martin A. | Chief Executive Officer | 5,823 0.0382% | $0.84 | $4,900 | +28.27% | ||
| 2023-02-13 | Lehr Martin A. | Chief Executive Officer | 5,606 0.0365% | $0.87 | $4,901 | +22.21% | ||
| 2023-02-06 | Lehr Martin A. | Chief Executive Officer | 5,040 0.032% | $0.97 | $4,900 | +6.25% | ||
| 2023-01-30 | Lehr Martin A. | Chief Executive Officer | 7,027 0.0449% | $0.70 | $4,901 | +47.88% | ||
| 2023-01-23 | Lehr Martin A. | Chief Executive Officer | 6,839 0.0434% | $0.72 | $4,901 | +42.86% | ||
| 2023-01-17 | Lehr Martin A. | Chief Executive Officer | 6,783 0.0442% | $0.74 | $4,995 | +42.66% | ||
| 2022-12-16 | Lehr Martin A. | Chief Executive Officer | 20,000 0.1253% | $0.74 | $14,796 | +26.06% | ||
| 2022-12-16 | Minai-Azary Jennifer Lynn | Chief Financial Officer | 25,000 0.1566% | $0.74 | $18,500 | +26.06% | ||
| 2022-12-09 | Levit Alex C. | Chief Legal Officer, Corp. Sec | 6,000 0.0384% | $0.85 | $5,095 | +11.23% | ||
| 2022-08-19 | Lehr Martin A. | Chief Executive Officer | 13,000 0.0824% | $1.85 | $24,064 | -42.90% | ||
| 2022-08-17 | Minai-Azary Jennifer Lynn | Chief Financial Officer | 15,000 0.0939% | $1.80 | $27,000 | -41.67% | ||
| 2022-08-16 | Sahmoud Tarek | Chief Medical Officer | 10,000 0.0636% | $1.95 | $19,500 | -45.05% | ||
| 2021-12-16 | Lehr Martin A. | Chief Executive Officer | 13,000 0.4558% | $3.22 | $41,850 | -41.36% | ||
| 2021-10-22 | Lehr Martin A. | Chief Executive Officer | 10,000 0.2524% | $5.00 | $50,000 | -71.82% | ||
| 2021-10-22 | Levit Alex C. | Chief Legal Officer, Corp. Sec | 3,000 0.0757% | $5.00 | $15,000 | -71.82% |
| Lehr Martin A. | Chief Executive Officer | 920190 1.0015% | $966,199.50 | 11 | 0 | +6.01% |
| Minai-Azary Jennifer Lynn | Chief Financial Officer | 80010 0.0871% | $84,010.50 | 3 | 0 | <0.0001% |
| Levit Alex C. | Chief Legal Officer, Corp. Sec | 29000 0.0316% | $30,450.00 | 3 | 0 | <0.0001% |
| Sahmoud Tarek | Chief Medical Officer | 10000 0.0109% | $10,500.00 | 1 | 0 | <0.0001% |
$17,525,882 | 60 | 5.22% | $87.83M | |
$4,898,715 | 46 | 40.75% | $110.93M | |
$16,259,194 | 41 | 120.51% | $86.42M | |
$7,147,964 | 34 | 24.78% | $112.08M | |
$160,539,875 | 21 | -6.57% | $95.2M | |
$38,821,584 | 20 | -2.17% | $86.66M | |
$7,733,516 | 17 | 73.42% | $103.31M | |
$3,331,968 | 17 | -23.79% | $94.05M | |
Context Therapeutics Inc. (CNTX) | $245,302 | 15 | -4.08% | $96.47M |
$277,862 | 15 | 59.79% | $98.58M | |
$18,563,605 | 15 | 48.91% | $91.06M | |
$15,799,576 | 12 | -39.52% | $94.72M | |
$145,194 | 11 | -27.37% | $103.25M | |
$135,589,307 | 10 | 32.46% | $100.43M | |
$99,355,998 | 7 | -65.74% | $112.67M | |
$68,692,148 | 6 | -39.10% | $104.89M | |
$105,079 | 4 | -41.57% | $92.85M | |
$657,791 | 4 | -52.05% | $89.51M | |
$16,554 | 2 | 41.65% | $100.02M |
| Increased Positions | 12 | +24% | 2M | +2.57% |
| Decreased Positions | 15 | -30% | 3M | -3.33% |
| New Positions | 6 | New | 282,088 | New |
| Sold Out Positions | 8 | Sold Out | 2M | Sold Out |
| Total Postitions | 47 | -6% | 76M | -0.76% |
| Mpm Bioimpact Llc | $16,471.00 | 15.99% | 14.71M | 0 | 0% | 2025-09-30 |
| Avidity Partners Management Lp | $10,060.00 | 9.76% | 8.98M | +2M | +20.12% | 2025-09-30 |
| Nextech Invest Ltd. | $8,310.00 | 8.07% | 7.42M | 0 | 0% | 2024-12-31 |
| Nextech Invest, Ltd. | $8,310.00 | 8.07% | 7.42M | 0 | 0% | 2025-09-30 |
| Deep Track Capital, Lp | $8,310.00 | 8.07% | 7.42M | 0 | 0% | 2025-09-30 |
| Blue Owl Capital Holdings Lp | $8,297.00 | 8.05% | 7.41M | 0 | 0% | 2025-09-30 |
| Great Point Partners I Lp | $5,246.00 | 5.09% | 4.68M | 0 | 0% | 2025-09-30 |
| Franklin Resources Inc | $4,484.00 | 4.35% | 4M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $3,914.00 | 3.8% | 3.5M | +134,449 | +4% | 2025-09-30 |
| Blackstone Inc. | $2,733.00 | 2.65% | 2.44M | 0 | 0% | 2025-09-30 |